ABUS · NASDAQ · Biotechnology

Arbutus Biopharma (ABUS)

Develops chronic HBV therapies while monetizing legacy lipid-nanoparticle IP.

$5.01
vs last close+0.00 (+0.10%)
  1. Arbutus (ABUS) Q2 Revenue Surges 529%

    The Motley Fool